ArticleViral immunology2009
Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV.
Article in Viral immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis.Journal of gynecologic oncology · 2022Pooled it
- Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2016Pooled it
- Recurrent Cervical HPV16 DNA Detection in Unvaccinated Women According to Presumed HPV16 Exposure Based on IgG and IgM Seroreactivity.Journal of medical virology · 2026Article
- Naturally developed HPV16 antibodies and risk of newly detected cervical HPV infection outcomes.Journal of medical virology · 2024Article
- Article
- Review
- Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.American journal of epidemiology · 2016Article
- Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.International journal of cancer · 2016Article
- Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study.Cancer research · 2016Article
- A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.Sexually transmitted diseases · 2015Article
- Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.The Journal of infectious diseases · 2014Article
- Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile.BMC infectious diseases · 2014Article
- Article
- Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women.Journal of medical virology · 2013Article
- Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.The Journal of infectious diseases · 2013Article
- Review
- Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types.The Journal of infectious diseases · 2012Article
- Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.International journal of cancer · 2012Article
- Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2012Review
- The known unknowns of HPV natural history.The Journal of clinical investigation · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Whether persistent human papillomavirus (HPV) IgG antibodies following natural infection are protective against subsequent infection is unknown. In a cohort of 508 college women followed for 3 y, persistent seropositivity was defined as the presence of type-specific HPV virus-like particle (VLP) antibodies at > or = 2 consecutive visits 1 y apart. Protection from incident infection with any HPV was conferred by persistent antibodies to HPV16 (p = 0.02), HPV31 (p < 0.001), HPV33 (p = 0.03), HPV35 (p = 0.002), HPV52 (p = 0.007), HPV45 (p = 0.003), and HPV53 (p = 0.01). The risk of incident infection with species-specific HPV types was also decreased in women with persistent antibodies to any HPV type in that group, suggesting that exposure to HPV with persistent development of antibody response can be protective, and may explain the decreased efficacy of HPV vaccine in women with prior exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.